Pyrotinib, a novel pan-ErbB inhibitor developed in China, showed promising anticancer activity in both a preclinical study and phase II clinical trial in patients with HER2-mutated NSCLC, who had previously undergone chemotherapy, exhibiting an ORR of 30–53%, and a manageable safety profile.73 The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.